Document text
U.S. Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases
Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation
use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.
2024 -25 Influenza Season Update and Seasonal Influenza
Vaccine Recommendations for the 2025 -26 U.S. Influenza
Season
Dr. Vivien Dugan
Influenza Division, CDC/NCIRD
June 26, 2025
2024 -25 influenza season summary
Proposed updates to the seasonal influenza vaccine recommendations
for the 2025 -26 influenza season including the following recent FDA
approvals:
–Influenza vaccine composition for the 2025 -26 season
–FluMist (live attenuated influenza vaccine, trivalent) for self -or caregiver
administration
–Change in age indication for Flublok (recombinant influenza vaccine, trivalent)
from ≥18 years to ≥9 yearsOverview
2
2024 -25 Influenza Season
High severity season overall and for all age groups
–First high severity season since 2017 -2018
Highest cumulative influenza -associated hospitalization rate since
2010 -2011
–October 1, 2024 through April 30, 2025: 128.1 per 100,000
–Cumulative rate was 102.9 per 100,000 for the severe 2017 -18 season
As of June 7, 246 influenza -associated pediatric deaths have been
reported this season2024 -25 U.S. Influenza Season
4Weekly US Influenza Surveillance Report: Key Updates for Week 20, ending May 17, 2025 | FluView | CDC
Weekly US Influenza Surveillance Report: Key Updates for Week 23, ending June 7, 2025 | FluView | CDC
Influenza -Associated Hospitalizations, FluSurv -NET, 2024 -
2025 Season
Lab -confirmed influenza -associated hospitalizations in
select counties in 14 states
Approx. 9% of U.S. population
As of May 17, cumulative rate of 128.1 per 100,00
–Was 102.9 for 2017 -18
Approx 16% of hospitalized patients required ICU
admission and 6% required invasive mechanical ventilation
Weekly US Influenza Surveillance Report: Key Updates for Week 20, ending May 17, 2025 | FluView | CDC5103.4
39.8 51.9149.7403.4
0100200300400500
0-4 5-17 18-49 50-64 ≥65Rate (per 100,000 population)
Age groupCumulative rate of laboratory -confirmed influenza
hospitalizations by age - FluSurv -NET, 2024 -25 season102.9
020406080100120140Rate per 100,000 population
Influenza SeasonCumulative rate of laboratory -confirmed influenza
hospitalizations by season –– FluSurv- NET, 2010- 11 – 2024 -25
seasons
128.1
Influenza- Associated Pediatric Mortality,
2024 -2025 Season*
Death in a person <18 yrs of age
–with clinically compatible illness
–and influenza positive laboratory test
–and no period of complete recovery
between illness and death
Nationally notifiable since 2004
246 deaths reported*
All age groups affected
•0-5 months: 7%
•6-23 months: 13%
•2-4 years: 18%
•5-11 years: 37%
•12-17 years: 26%
* Through June 7, 2025 https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html 6
Influenza- Associated Pediatric Mortality,
2024 -2025 Season*
Among 246 influenza -associated pediatric deaths reported thus far
for 2024-25*,
–42% had no known high risk underlying medical condition
–40% had a bacterial co -infection of a sterile site
–89% of those eligible for influenza vaccination were not fully vaccinated
•Compared with 82% for the 2023 -24 season
Highest number of pediatric deaths reported in any non -pandemic
influenza season since condition became reportable in 2004
* Through June 7, 2025 https://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html 7
2025 -26 Seasonal Influenza Vaccine
Recommendations
8
Annual influenza vaccination remains recommended for those aged
≥6 months who do not have contraindications
As previously,
–No preferential recommendations are made with the exception that high- dose
inactivated, recombinant, and adjuvanted inactivated influenza vaccines are
preferentially recommended for persons aged ≥65 years when available
–Recipients should receive an age -appropriate influenza vaccine (one approved for
their age), with the exception that solid organ transplant recipients aged ≥18 years who are taking immunosuppressive medications regimens may receive either high- dose or adjuvanted inactivated vaccines (without preference over
other appropriate influenza vaccines)
Recommendations concerning timing, vaccine selection, and
contraindications and precautions remain the same as previouslySeasonal Influenza Vaccine Recommendations, 2025 -26
9 MMWR 2024;73(RR- 5):1-25
The 2025 -26 recommendations include three updates, all of which
reflect recent FDA approvals:
–Influenza vaccine composition for the 2025 -26 season
–FluMist (live attenuated influenza vaccine, trivalent; LAIV3) for self - or caregiver
administration
–Change in age indication for Flublok (recombinant influenza vaccine, trivalent;
RIV3) from ≥18 years to ≥9 yearsRecommendations for 2025 -26: Updates
10
All influenza vaccines marketed in the United States for the 2025 -26
season will be trivalent
U.S. influenza vaccine composition for 2025 -26 includes an update to
the influenza A(H3N2) component:
–AnA/Victoria/4897/2022 (H1N1)pdm09 -like virus for egg -based vaccines
or an A/Wisconsin/67/2022 (H1N1)pdm09 -like virus for cell and recombinant
vaccines;
–An A/Croatia/Y10136RV/2023 (H3N2)- like virus for egg -based vaccines
or an A/District of Columbia/27/2023 (H3N2) -like virus for cell and recombinant
vaccines;
–A B/Austria/1359417/2021 (B/Victoria lineage)- like virusU.S. Influenza Vaccine Composition for the 2025 -26
Influenza Season
Influenza Vaccine Composition for the 2025 -2026 U.S. Influenza Season | FDA 11
Approved by FDA in September 20241; presented to ACIP in April 2025
Anticipated to be available for the 2025 -26 influenza season
Consumers will be able to order FluMist for delivery for eligible
recipients
–Screening for eligibility performed by central pharmacy, based on ACIP criteria
–Approved for self- administration for persons aged ≥18 years, or by a caregiver
aged ≥18 years for recipients aged 2 through 17 years
LAIV3 will continue to be available for administration by healthcare
providers as previously
No changes made to recommendations regarding appropriate populations, contraindications, or precautionsFluMist (LAIV3) for Self- or Caregiver Administration
12 1.https://www.fda.gov/vaccines -blood -biologics/vaccines/flumist
Approved by FDA in March 20251
Previously approved for ≥18 years; new age indication is ≥9 years
Information has been updated in the Table of available U.S. influenza
vaccines for 2025 -26Approval of Flublok (RIV3) for Persons Aged 9 through 17
Years
1.https://www.fda.gov/vaccines -blood -biologics/vaccines/flublok 13
For more information, contact CDC
1-800- CDC- INFO (232 -4636)
TTY: 1 -888 -232-6348 www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official
position of the Centers for Disease Control and Prevention.
Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation
use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.
14